Sprycel Related Clinical Trials
Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia [Recruiting]
Ph I Dasatinib + Erlotinib in Recurrent MG [Recruiting]
Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma [Recruiting]
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib [Recruiting]
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) [Recruiting]
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer [Recruiting]
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib [Recruiting]
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) [Recruiting]
Dasatinib and Crizotinib in Advanced Cancer [Not yet recruiting]
Phase I/II - Dasatinib and Decitabine [Recruiting]
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia [Recruiting]
Effects of Gastric pH on the Pharmacokinetics of Dasatinib [Recruiting]
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor [Recruiting]
Study of Dasatinib in Patients With Chronic Myelogenous Leukemia [Recruiting]
Personalized Treatment Selection for Dasatinib in Metastatic Breast Cancer [Recruiting]
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 [Recruiting]
Dasatinib in Resectable Malignant Pleural Mesothelioma [Recruiting]
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC [Recruiting]
Dasatinib (Sprycelâ„¢) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) [Recruiting]
A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Recruiting]
Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease [Recruiting]
Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate [Recruiting]
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer [Recruiting]
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial [Recruiting]
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in NNSCC [Recruiting]
Dasatinib Combo With SMO Inhibitor (BMS-833923) [Recruiting]
Study of Erlotinib in Combination With Dasatinib [Recruiting]
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma [Recruiting]
Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant [Recruiting]
Dasatinib in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma [Recruiting]
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies [Recruiting]
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery [Recruiting]
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic [Recruiting]
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib [Not yet recruiting]
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer [Recruiting]
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies [Recruiting]
A Phase I/Expansion Study of Dasatinib [Recruiting]
Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer [Recruiting]
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) [Recruiting]
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer [Recruiting]
Study of BMS-354825 in Children and Adolescents With Relapsed or Refractory Leukemia [Recruiting]
Phase I Dasatinib/Erlotinib in Recurrent NSCLC [Recruiting]
Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL [Recruiting]
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis [Recruiting]
Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation [Recruiting]
Dasatinib in Patients With Head and Neck Squamous Cell Carcinoma [Recruiting]
PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer [Recruiting]
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer [Recruiting]
Solid Tumors Using Ixabepilone and Dasatinib [Recruiting]
Safety Study of Dasatinib With Bortezomib for Multiple Myeloma [Recruiting]
Dasatinib in Relapsed Chronic Lymphocytic Leukemia [Recruiting]
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma [Recruiting]
Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts [Recruiting]
Dasatinib in Combination With Revlimid (and Dexamethasone) [Recruiting]
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML [Recruiting]
Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder [Recruiting]
Phase II Dasatinib Study in Advanced Breast Cancer [Recruiting]
A Phase I/II Study of Dasatinib and Dacarbazine [Recruiting]
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer [Recruiting]
Study of Dasatinib in Patients With Chronic Phase CML and a Suboptimal Response to Imatinib [Recruiting]
Gemcitabine and Dasatinib in Advanced Solid Tumors [Recruiting]
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis [Not yet recruiting]
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Accelerated Phase) Subjects [Recruiting]
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer [Recruiting]
Dasatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Recruiting]
Dastinib in Polycythemia Vera [Recruiting]
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer [Recruiting]
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery [Recruiting]
Treatment of Adult Ph+ LAL With BMS-354825 [Recruiting]
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer [Recruiting]
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate [Recruiting]
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor [Recruiting]
Ph. I Dasatinib/Protracted Temo in Recurrent Malignant Glioma [Not yet recruiting]
Trial of Dasatinib in Advanced Sarcomas [Recruiting]
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia [Recruiting]
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors [Recruiting]
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer [Recruiting]
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer [Recruiting]
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma [Recruiting]
Dasatinib and Lapatinib in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery [Not yet recruiting]
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer [Recruiting]
Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer [Recruiting]
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma [Recruiting]
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Recruiting]
|
